Related references
Note: Only part of the references are listed.Identification of Oncostatin M as a STAT5-Dependent Mediator of Bone Marrow Remodeling in KIT D816V-Positive Systemic Mastocytosis
Gregor Hoermann et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
Ken-Hong Lim et al.
BLOOD (2009)
Functional and clinical consequences of Fc receptor polymorphic and copy number variants
S. Bournazos et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
L. L. Remsing Rix et al.
LEUKEMIA (2009)
The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils
Michael Kneidinger et al.
BLOOD (2008)
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis
Srdan Verstovsek et al.
CLINICAL CANCER RESEARCH (2008)
Unique effects of KIT D816V in BaF3 cells: Induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens
Matthias Mayerhofer et al.
JOURNAL OF IMMUNOLOGY (2008)
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets
Uwe Rix et al.
BLOOD (2007)
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT
Karoline Gleixner et al.
HAEMATOLOGICA (2007)
Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells
Karoline V. Gleixner et al.
EXPERIMENTAL HEMATOLOGY (2007)
The Btk tyrosine kinase is a major target of the Bcr-Abi inhibitor dasatinib
Oliver Hantschel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells
Rudin Kondo et al.
BLOOD (2007)
Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria
P. Valent et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2007)
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
Neil P. Shah et al.
BLOOD (2006)
Immunohistochemical detection of histidine decarboxytase in neoplastic mast cells in patients with systemic mastocytosis
MT Krauth et al.
HUMAN PATHOLOGY (2006)
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT:: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects
KV Gleixner et al.
BLOOD (2006)
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT Isoforms associated with human malignancies
MM Schittenhelm et al.
CANCER RESEARCH (2006)
Pathogenesis, clinical features, and treatment advances in mastocytosis
A. Pardanani et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2006)
Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation
JP Zappulla et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Positive and negative regulation of mast cell activation by Lyn via the FcεRI
WB Xiao et al.
JOURNAL OF IMMUNOLOGY (2005)
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
J Gotlib et al.
BLOOD (2005)
Activation mutations of human c-KIT resistant to imatinib, mesylate are sensitive to the tyrosine kinase inhibitor PKC412
JD Growney et al.
BLOOD (2005)
Stat5 tetramer formation is associated with leukemogenesis
R Moriggl et al.
CANCER CELL (2005)
Lyn contributes to regulation of multiple Kit-dependent signaling pathways in murine bone marrow mast cells
R Shivakrupa et al.
CELLULAR SIGNALLING (2005)
On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts
P Valent et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Systemic mastocytosis
C Akin et al.
ANNUAL REVIEW OF MEDICINE (2004)
Clinical, genetic, and therapeutic insights into systemic mast cell disease
A Tefferi et al.
CURRENT OPINION IN HEMATOLOGY (2004)
CD25 indicates the neoplastic phenotype of mast cells - A novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens
K Sotlar et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
Diagnosis and treatment of systemic mastocytosis: State of the art
P Valent et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit
C Akin et al.
EXPERIMENTAL HEMATOLOGY (2003)
Signal transducer and activator of transcription proteins in leukemias
M Benekli et al.
BLOOD (2003)
Mastocytosis: current concepts in diagnosis and treatment
L Escribano et al.
ANNALS OF HEMATOLOGY (2002)
The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells
A Klejman et al.
EMBO JOURNAL (2002)
Kit and c-kit mutations in mastocytosis:: A short overview with special reference to novel molecular and diagnostic concepts
F Féger et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2002)
Diagnostic criteria and classification of mastocytosis:: a consensus proposal
P Valent et al.
LEUKEMIA RESEARCH (2001)
Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis
R Fritsche-Polanz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
